Soy isoflavones

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Soy isoflavones
Accession Number
DB14101
Type
Small Molecule
Groups
Approved, Experimental
Description
Not Available
Synonyms
  • Soy germ isoflavones
  • Soybean isoflavones
  • Soybean isoflavoues
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cheon Shim Bo YunSoy isoflavones (30 mg/1) + D-alpha-Tocopherol acetate (3 mg/1) + N-Acetylglucosamine (263 mg/1)CapsuleOralSaimdang Cosmetics Co., Ltd2010-11-08Not applicableUs
D-Cal SoyCalSoy isoflavones (1 g/1) + Calcium Carbonate (28.32 g/1) + Cholecalciferol (480 ug/1)TabletOralA&Z Pharmaceutical, Inc.2010-01-22Not applicableUs
International/Other Brands
Solgen 40
Categories
Not Available
UNII
71B37NR06D
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Soybean

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableTherapeutic Agent Toxicity1
2CompletedTreatmentChronic Renal Failure (CRF)1
2CompletedTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Stage I Hypopharyngeal Squamous Cell Carcinoma / Stage I Laryngeal Squamous Cell Carcinoma / Stage I Laryngeal Verrucous Carcinoma / Stage I Lip and Oral Cavity Squamous Cell Carcinoma / Stage I Oral Cavity Verrucous Carcinoma / Stage I Oropharyngeal Squamous Cell Carcinoma / Stage II Hypopharyngeal Squamous Cell Carcinoma / Stage II Laryngeal Squamous Cell Carcinoma / Stage II Laryngeal Verrucous Carcinoma / Stage II Lip and Oral Cavity Squamous Cell Carcinoma / Stage II Oral Cavity Verrucous Carcinoma / Stage II Oropharyngeal Squamous Cell Carcinoma / Stage III Hypopharyngeal Squamous Cell Carcinoma / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Laryngeal Verrucous Carcinoma / Stage III Lip and Oral Cavity Squamous Cell Carcinoma / Stage III Oral Cavity Verrucous Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
4CompletedTreatmentMenopausal Hot Flushes1
4Unknown StatusTreatmentPostmenopausal Women With Moderate Vasomotor Symptoms1
Not AvailableCompletedNot AvailableMigrainous Headache1
Not AvailableCompletedTreatmentAsthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 20, 2018 09:19 / Updated on November 02, 2018 07:50